Recombinant Human PIM1 293 Cell Lysate

• Cat.No.: PIM1-3181HCL

Specification

• Description: Antigen standard for pim-1 oncogene (PIM1) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: PIM1 pim-1 oncogene [ Homo sapiens ]
• Official Symbol: PIM1
• Synonyms: PIM1; pim-1 oncogene; PIM; serine/threonine-protein kinase pim-1; Oncogene PIM1; pim-1 kinase 44 kDa isoform; pim-1 oncogene (proviral integration site 1); proto-oncogene serine/threonine-protein kinase pim-1
• Gene ID: 5292
• mRNA Refseq: NM_001243186
• Protein Refseq: NP_001230115
• MIM: 164960
• UniProt ID: P11309
• Chromosome Location: 6p21
• Pathway: Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem; C-MYB transcription factor network, organism-specific biosystem; IL-5 Signaling Pathway, organism-specific biosystem; Jak-STAT signaling pathway, organism-specific biosystem; Jak-STAT signaling pathway, conserved biosystem; Role of Calcineurin-dependent NFAT signaling in lymphocytes, organism-specific biosystem
• Function: ATP binding; manganese ion binding; metal ion binding; nucleotide binding; protein binding; protein serine/threonine kinase activity; transcription factor binding

Reviews

01/30/2022

With the combination of this protein reagent's instructions, I can easily accomplish experimental design and operation.

04/29/2020

With consistent and reliable results, this protein reagent is ideal for research projects that require replicability.

01/02/2020

Following the use of this protein reagent, the reproducibility of my experiments has significantly improved, and I am highly satisfied.

Q&As

What are the main substrates of PIM1 and how does their interaction affect cellular processes?

PIM1 phosphorylates a variety of substrates, including BAD, c-Myc, and eIF4B. Phosphorylation of BAD inhibits its pro-apoptotic function, while phosphorylation of c-Myc and eIF4B enhances their transcriptional and translational activities, promoting cell survival and protein synthesis, respectively.

How is PIM1 activity regulated by signaling pathways?

PIM1 activity is regulated by several signaling pathways, including the PI3K/AKT and JAK/STAT pathways. Activation of these pathways leads to the phosphorylation and activation of PIM1, while inhibition of these pathways can result in reduced PIM1 activity.

What is the potential of PIM1 as a prognostic marker or therapeutic target in different cancer types?

Further research is needed to assess the potential of PIM1 as a prognostic marker and therapeutic target in different cancer types. Understanding the specific roles of PIM1 in various cancers and its interactions with other signaling pathways will help determine its clinical relevance and potential utility in personalized cancer treatment strategies.

What role does PIM1 play in cancer development?

PIM1 has been implicated in promoting cell proliferation, survival, and resistance to apoptosis, contributing to cancer development. Its overexpression has been observed in various cancer types and is associated with poor prognosis. PIM1 also interacts with oncogenic signaling pathways, further promoting tumor growth and progression.

Are there any potential therapeutic strategies targeting PIM1?

Several small molecule inhibitors targeting PIM1 kinase activity have been developed and show promise as potential therapeutics. These inhibitors can selectively inhibit PIM1 activity and have demonstrated anti-tumor effects in preclinical studies. Combination therapy with PIM1 inhibitors and other targeted drugs may also be a viable approach for treating PIM1-driven cancers.

How does PIM1 regulate cell cycle progression and proliferation?

PIM1 regulates cell cycle progression and proliferation by phosphorylating key substrates, such as p27 and CDC25A, which control the activity of cyclin-dependent kinases (CDKs). This phosphorylation promotes the degradation of p27 and stabilizes CDC25A, leading to enhanced CDK activity and cell cycle progression.

How is PIM1 expression regulated at the transcriptional level?

PIM1 expression can be regulated by various factors, including cytokines, growth factors, and oncogenic signals. These factors can activate specific transcription factors, such as STAT3 and NF-κB, which bind to the PIM1 promoter and enhance its transcriptional activity, resulting in increased PIM1 expression.